Rivera Michelle L, Kim Tommy Y, Stewart Gail M, Minasyan Lilit, Brown Lance
Division of Pediatric Emergency Medicine, Department of Pediatrics, Children's Hospital of Michigan and Wayne State University School of Medicine, Detroit, 48201, USA.
Am J Emerg Med. 2006 Jan;24(1):38-42. doi: 10.1016/j.ajem.2005.06.007.
A prospective blinded, randomized controlled trial was undertaken to compare the initial response of albuterol nebulized in heliox or control in the treatment of moderately severe asthma in children presenting to a pediatric ED.
Patients were randomized to receive heliox (n = 20) or control (n = 21). The primary outcome was to compare a modified dyspnea index score at 10 and 20 minutes after randomization. Secondary outcomes were to determine if heliox decreased admission rates or endotracheal intubation.
There was no statistically significant difference found at 10 or 20 minutes after randomization with heliox (P = .169 and P = .062, respectively). No statistical difference in admission rate was found, and no patients required endotracheal intubation in either group.
Our results demonstrate that albuterol nebulized with heliox offered no clinical benefit over standard therapy in the initial treatment of moderately severe asthma in the ED.
开展一项前瞻性双盲随机对照试验，比较氦氧混合气雾化沙丁胺醇与对照组对儿科急诊科中重度哮喘患儿的初始治疗反应。
将患者随机分为接受氦氧混合气组（n = 20）或对照组（n = 21）。主要结局是比较随机分组后10分钟和20分钟时改良呼吸困难指数评分。次要结局是确定氦氧混合气是否降低了住院率或气管插管率。
随机分组后10分钟或20分钟时，氦氧混合气组无统计学显著差异（分别为P = 0.169和P = 0.062）。两组住院率无统计学差异，且两组均无患者需要气管插管。
我们的结果表明，在急诊科对中重度哮喘进行初始治疗时，氦氧混合气雾化沙丁胺醇与标准治疗相比无临床益处。
Zotero 插件